GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market
Phase III Study Misses Endpoint
Executive Summary
The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.
You may also be interested in...
First Gene Editing Therapy Among Seven Drugs On Track For EU-Wide Approval
The European Medicines Agency has recommended seven new drugs for EU-wide approval, and OKd two others under its EU-M4all procedure that is meant for high-priority human medicines intended for markets outside the EU.
Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain
GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.
Five Clinical Trial Misses Of 2022
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.